| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2012PNAS..109.9448K |
| P356 | DOI | 10.1073/PNAS.1201840109 |
| P932 | PMC publication ID | 3386114 |
| P698 | PubMed publication ID | 22566629 |
| P5875 | ResearchGate publication ID | 224919019 |
| P50 | author | Thomas Moore-Morris | Q38643372 |
| David A. Brenner | Q44296012 | ||
| Christopher K Glass | Q55458945 | ||
| Chris Benner | Q79949523 | ||
| P2093 | author name string | Tatiana Kisseleva | |
| Sylvia M Evans | |||
| Hidekazu Tsukamoto | |||
| Brian Scott | |||
| David Scholten | |||
| Wolfgang Dillmann | |||
| Keiko Iwaisako | |||
| Chunyan Jiang | |||
| Min Cong | |||
| Yonghan Paik | |||
| P2860 | cites work | Hsp72-mediated suppression of c-Jun N-terminal kinase is implicated in development of tolerance to caspase-independent cell death | Q24290139 |
| Senescence of activated stellate cells limits liver fibrosis | Q24621822 | ||
| Ito cells are liver-resident antigen-presenting cells for activating T cell responses | Q28284291 | ||
| Activation of hepatic stellate cells by TGF alpha and collagen type I is mediated by oxidative stress through c-myb expression | Q28367828 | ||
| Foxf1 +/- mice exhibit defective stellate cell activation and abnormal liver regeneration following CCl4 injury | Q28504652 | ||
| Liver fibrosis | Q29547449 | ||
| TLR4 enhances TGF-beta signaling and hepatic fibrosis | Q29620016 | ||
| Multiparameter flow cytometry of fluorescent protein reporters | Q31049416 | ||
| Restoration of podocyte structure and improvement of chronic renal disease in transgenic mice overexpressing renin | Q33495583 | ||
| Antiapoptotic and anti-inflammatory mechanisms of heat-shock protein protection | Q36265291 | ||
| Early growth response gene 1-mediated apoptosis is essential for transforming growth factor beta1-induced pulmonary fibrosis | Q36399732 | ||
| The role of matrix stiffness in regulating cell behavior | Q37096921 | ||
| Mesenchymal origin of hepatic stellate cells, submesothelial cells, and perivascular mesenchymal cells during mouse liver development | Q37169108 | ||
| Hepatic lipocytes: the principal collagen-producing cells of normal rat liver | Q37558514 | ||
| Adipogenic transcriptional regulation of hepatic stellate cells | Q38334417 | ||
| Mechanisms of spontaneous resolution of rat liver fibrosis. Hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors | Q39807542 | ||
| A non-toxic heat shock protein 70 inducer, geranylgeranylacetone, suppresses apoptosis of cultured rat hepatocytes caused by hydrogen peroxide and ethanol | Q43701056 | ||
| Gliotoxin stimulates the apoptosis of human and rat hepatic stellate cells and enhances the resolution of liver fibrosis in rats | Q43720079 | ||
| DNase I-hypersensitive sites enhance alpha1(I) collagen gene expression in hepatic stellate cells | Q44286483 | ||
| Intragastric ethanol infusion model in rodents | Q46679808 | ||
| Cre recombinase-mediated gene targeting of mesenchymal cells | Q47867267 | ||
| 5' stem-loop of collagen alpha 1(I) mRNA inhibits translation in vitro but is required for triple helical collagen synthesis in vivo. | Q53817861 | ||
| The endocannabinoid 2-arachidonoyl glycerol induces death of hepatic stellate cells via mitochondrial reactive oxygen species | Q57373891 | ||
| Enhanced human cell engraftment in mice deficient in RAG2 and the common cytokine receptor gamma chain | Q58478774 | ||
| Cotransplanted hepatic stellate cells enhance vascularization of islet allografts | Q80261145 | ||
| Adipogenic phenotype of hepatic stellate cells | Q81607059 | ||
| P433 | issue | 24 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | phenotype | Q104053 |
| P1104 | number of pages | 6 | |
| P304 | page(s) | 9448-9453 | |
| P577 | publication date | 2012-05-07 | |
| P1433 | published in | Proceedings of the National Academy of Sciences of the United States of America | Q1146531 |
| P1476 | title | Myofibroblasts revert to an inactive phenotype during regression of liver fibrosis | |
| P478 | volume | 109 |
| Q90354283 | "Let my liver rather heat with wine" - a review of hepatic fibrosis pathophysiology and emerging therapeutics |
| Q90248736 | A Deactivation Factor of Fibrogenic Hepatic Stellate Cells Induces Regression of Liver Fibrosis in Mice |
| Q45864008 | A Proof-of-Concept for Epigenetic Therapy of Tissue Fibrosis: Inhibition of Liver Fibrosis Progression by 3-Deazaneplanocin A. |
| Q39376604 | A mouse model of alcoholic liver fibrosis-associated acute kidney injury identifies key molecular pathways |
| Q47185568 | A new technique to improve the mechanical and biological performance of ultra high molecular weight polyethylene using a nylon coating. |
| Q42368725 | Aberrant SSEA-4 upregulation mediates myofibroblast activity to promote pre-cancerous oral submucous fibrosis |
| Q36651943 | Absence of Nogo-B (reticulon 4B) facilitates hepatic stellate cell apoptosis and diminishes hepatic fibrosis in mice |
| Q36961774 | Activation of cardiac fibroblasts by ethanol is blocked by TGF-β inhibition |
| Q28543721 | Adiponectin agonist ADP355 attenuates CCl4-induced liver fibrosis in mice |
| Q42307037 | Adverse outcome pathways: opportunities, limitations and open questions |
| Q39110924 | Aging enhances liver fibrotic response in mice through hampering extracellular matrix remodeling |
| Q60046008 | Alcoholic liver disease: Utility of animal models |
| Q37489144 | Amelioration of radiation-induced pulmonary fibrosis by a water-soluble bifunctional sulfoxide radiation mitigator (MMS350). |
| Q36949952 | An in vitro culture system for long-term expansion of epithelial and mesenchymal salivary gland cells: role of TGF-β1 in salivary gland epithelial and mesenchymal differentiation |
| Q26781761 | Animal Models for Fibrotic Liver Diseases: What We Have, What We Need, and What Is under Development |
| Q40394506 | Antifibrotic Effects of Human Amniotic Membrane Transplantation in Established Biliary Fibrosis Induced in Rats |
| Q38480164 | Antifibrotic therapies in the liver |
| Q39238770 | Antifibrotics in chronic liver disease: tractable targets and translational challenges |
| Q33713723 | Apoptosis and angiogenesis: an evolving mechanism for fibrosis |
| Q38927192 | Assessment of Hepatic Impairment and Implications for Pharmacokinetics of Substance Use Treatment |
| Q24658641 | B-cell depletion attenuates serological biomarkers of fibrosis and myofibroblast activation in IgG4-related disease |
| Q91997750 | Biological heterogeneity and versatility of cancer-associated fibroblasts in the tumor microenvironment |
| Q27021576 | Bone marrow-derived fibrocytes contribute to liver fibrosis |
| Q38259727 | Cardiac valve cells and their microenvironment--insights from in vitro studies |
| Q38311151 | Cellular and molecular functions of hepatic stellate cells in inflammatory responses and liver immunology |
| Q33685938 | Cellular and molecular mechanisms in kidney fibrosis |
| Q36763871 | Cellular mechanisms of tissue fibrosis. 3. Novel mechanisms of kidney fibrosis |
| Q27021577 | Cellular mechanisms of tissue fibrosis. 5. Novel insights into liver fibrosis |
| Q27003892 | Cellular mechanisms of tissue fibrosis. 7. New insights into the cellular mechanisms of pulmonary fibrosis |
| Q57034602 | Cellular network modeling and single cell gene expression analysis reveals novel hepatic stellate cell phenotypes controlling liver regeneration dynamics |
| Q35896870 | Characterization of animal models for primary sclerosing cholangitis (PSC). |
| Q40262971 | Characterization of hepatic stellate cells, portal fibroblasts, and mesothelial cells in normal and fibrotic livers |
| Q40560942 | Constrictive Bronchiolitis in Cystic Fibrosis Adolescents with Refractory Pulmonary Decline |
| Q28083363 | Contribution of bone marrow-derived fibrocytes to liver fibrosis |
| Q49331101 | Control of cell morphology and differentiation by substrates with independently tunable elasticity and viscous dissipation. |
| Q38269986 | Cre-ativity in the liver: transgenic approaches to targeting hepatic nonparenchymal cells |
| Q64068193 | Critical Role of Cysteine-Rich Protein 61 in Mediating the Activation of Renal Fibroblasts |
| Q49922983 | Critical effects of long non-coding RNA on fibrosis diseases |
| Q38841405 | Cytoglobin expression in the hepatic stellate cell line HSC-T6 is regulated by extracellular matrix proteins dependent on FAK-signalling |
| Q37358947 | Deactivation of hepatic stellate cells during liver fibrosis resolution in mice. |
| Q38982080 | Defining the Cardiac Fibroblast |
| Q41668387 | Deletion of the collagen-specific molecular chaperone Hsp47 causes endoplasmic reticulum stress-mediated apoptosis of hepatic stellate cells |
| Q40390545 | Deregulated neddylation in liver fibrosis |
| Q38287306 | Determining the fate of hepatic cells by lineage tracing: facts and pitfalls |
| Q38303313 | Early to Phase II drugs currently under investigation for the treatment of liver fibrosis |
| Q39412233 | Editor's Highlight: Modeling Compound-Induced Fibrogenesis In Vitro Using Three-Dimensional Bioprinted Human Liver Tissues |
| Q92219387 | Epigenetic Mechanisms in Hepatic Stellate Cell Activation During Liver Fibrosis and Carcinogenesis |
| Q38985933 | Epigenetic regulation of hepatic stellate cell activation and liver fibrosis |
| Q35196346 | Epimorphin alters the inhibitory effects of SOX9 on Mmp13 in activated hepatic stellate cells. |
| Q34425579 | Ergosterol Is the Active Compound of Cultured Mycelium Cordyceps sinensis on Antiliver Fibrosis |
| Q36615739 | Essential Roles of RNA-binding Protein HuR in Activation of Hepatic Stellate Cells Induced by Transforming Growth Factor-β1 |
| Q91621157 | Evasion of apoptosis by myofibroblasts: a hallmark of fibrotic diseases |
| Q30539166 | Evolving therapies for liver fibrosis |
| Q37363773 | Experimental liver fibrosis research: update on animal models, legal issues and translational aspects |
| Q36442525 | Experimental models of liver fibrosis |
| Q50420061 | Extracellular matrix in lung development, homeostasis and disease |
| Q33762356 | Fate tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its aetiology. |
| Q47285409 | Fibroblasts Promote Inflammation and Pain via Interleukin-1α-Induction of the Monocyte Chemoattractant CCL2. |
| Q34309876 | Fibrogenesis and Carcinogenesis in Nonalcoholic Steatohepatitis (NASH): Involvement of Matrix Metalloproteinases (MMPs) and Tissue Inhibitors of Metalloproteinase (TIMPs). |
| Q36066433 | Fibrogenic cell reversion underlies fibrosis regression in liver |
| Q90138987 | Fibrosis and cancer: A strained relationship |
| Q40556586 | Fibrosis is not just fibrosis - basement membrane modelling and collagen metabolism differs between hepatitis B- and C-induced injury |
| Q102389095 | Fibrosis: from mechanisms to medicines |
| Q45024723 | Fra, Fra away: the complex role of activator protein 1 in liver injury |
| Q38723925 | Functional Immune Anatomy of the Liver-As an Allograft |
| Q90702784 | Functional heterogeneity of resident fibroblasts in the kidney |
| Q58574738 | Galectin-1 gene silencing inhibits the activation and proliferation but induces the apoptosis of hepatic stellate cells from mice with liver fibrosis |
| Q35977791 | Gas6/Axl pathway is activated in chronic liver disease and its targeting reduces fibrosis via hepatic stellate cell inactivation |
| Q90469547 | Gas6/TAM Signaling Components as Novel Biomarkers of Liver Fibrosis |
| Q35073234 | Gene expression profiling of early hepatic stellate cell activation reveals a role for Igfbp3 in cell migration |
| Q33907038 | Generation and analysis of spheroids from human primary skin myofibroblasts: an experimental system to study myofibroblasts deactivation |
| Q28392538 | Genetic tools for identifying and manipulating fibroblasts in the mouse |
| Q96348274 | Ginsenoside Rg3 promotes regression from hepatic fibrosis through reducing inflammation-mediated autophagy signaling pathway |
| Q36999185 | Gradually softening hydrogels for modeling hepatic stellate cell behavior during fibrosis regression |
| Q57109165 | Gulf war illness-related chemicals increase CD11b/c monocyte infiltration into the liver and aggravate hepatic cholestasis in a rodent model |
| Q64084368 | HDAC Inhibitors: Therapeutic Potential in Fibrosis-Associated Human Diseases |
| Q36588493 | HDAC inhibitors in experimental liver and kidney fibrosis |
| Q64111571 | HSC-specific knockdown of GGPPS alleviated CCl-induced chronic liver fibrosis through mediating RhoA/Rock pathway |
| Q26825838 | Healing scars: targeting pericytes to treat fibrosis |
| Q36799703 | Hedgehog pathway and pediatric nonalcoholic fatty liver disease |
| Q40453944 | Hepatic Stellate Cell Selective Disruption of Dynamin-2 GTPase Increases Murine Fibrogenesis through Up-Regulation of Sphingosine-1 Phosphate-Induced Cell Migration. |
| Q37629675 | Hepatic inflammation and progressive liver fibrosis in chronic liver disease |
| Q37359114 | Hepatic macrophages but not dendritic cells contribute to liver fibrosis by promoting the survival of activated hepatic stellate cells in mice. |
| Q48258986 | Hepatic perivascular mesenchymal stem cells with myogenic properties |
| Q89841259 | Hepatic stellate cell activation promotes alcohol-induced steatohepatitis through Igfbp3 and SerpinA12 |
| Q38176402 | Hepatic stellate cells and extracellular matrix in hepatocellular carcinoma: more complicated than ever. |
| Q34387063 | Hepatic stellate cells and liver fibrosis |
| Q40200602 | Hepatic stellate cells as key target in liver fibrosis |
| Q36793474 | Hepatic stellate cells in liver development, regeneration, and cancer |
| Q38103362 | Hepatic stem cell niches |
| Q90698951 | Hepatocyte and stellate cell deletion of liver fatty acid binding protein reveals distinct roles in fibrogenic injury |
| Q38560320 | Hepatocytes in liver injury: Victim, bystander, or accomplice in progressive fibrosis? |
| Q36380251 | High-Magnitude and/or High-Frequency Mechanical Strain Promotes Peripapillary Scleral Myofibroblast Differentiation. |
| Q27310369 | High-yield and high-purity isolation of hepatic stellate cells from normal and fibrotic mouse livers |
| Q26742049 | Homing in on the hepatic scar: recent advances in cell-specific targeting of liver fibrosis |
| Q26852800 | Host responses in tissue repair and fibrosis |
| Q45931088 | Human hepatic stellate cell isolation and characterization. |
| Q92656928 | Human induced pluripotent stem cell-derived extracellular vesicles reduce hepatic stellate cell activation and liver fibrosis |
| Q38544274 | Human liver myofibroblasts during development and diseases with a focus on portal (myo)fibroblasts |
| Q33711663 | Hydrogels with differential and patterned mechanics to study stiffness-mediated myofibroblastic differentiation of hepatic stellate cells |
| Q38700034 | Identification of Novel Fibrosis Modifiers by In Vivo siRNA Silencing |
| Q34389943 | Impaired endothelium-mesenchymal stem cells cross-talk in systemic sclerosis: a link between vascular and fibrotic features |
| Q90213513 | Impaired integrin α5 /β1 -mediated hepatocyte growth factor release by stellate cells of the aged liver |
| Q35923294 | In vitro reversion of activated primary human hepatic stellate cells |
| Q43236310 | Inactivation of myofibroblasts during regression of liver fibrosis |
| Q37325619 | Increase in cellular cyclic AMP concentrations reverses the profibrogenic phenotype of cardiac myofibroblasts: a novel therapeutic approach for cardiac fibrosis |
| Q36568239 | Induction and contribution of beta platelet-derived growth factor signalling by hepatic stellate cells to liver regeneration after partial hepatectomy in mice |
| Q92861341 | Inflammation and fibrosis in chronic liver diseases including non-alcoholic fatty liver disease and hepatitis C |
| Q34381832 | Inhibition of a novel fibrogenic factor Tl1a reverses established colonic fibrosis |
| Q36638211 | Inhibition of mechanosensitive signaling in myofibroblasts ameliorates experimental pulmonary fibrosis |
| Q33975195 | Inhibitory effect of tanshinone IIA on rat hepatic stellate cells |
| Q63984750 | Insulin resistance disrupts epithelial repair and niche-progenitor Fgf signaling during chronic liver injury |
| Q28273742 | Interaction of TWEAK with Fn14 leads to the progression of fibrotic liver disease by directly modulating hepatic stellate cell proliferation |
| Q41661762 | Intestinal fungi contribute to development of alcoholic liver disease. |
| Q61798333 | Iron and liver fibrosis: Mechanistic and clinical aspects |
| Q52925783 | Isolation and time lapse microscopy of highly pure hepatic stellate cells. |
| Q45893509 | It has to be the αv: myofibroblast integrins activate latent TGF-β1. |
| Q34176024 | Kidney pericytes: roles in regeneration and fibrosis. |
| Q38729032 | Ligustrazine-Oleanolic Acid Glycine Derivative, G-TOA, Selectively Inhibited the Proliferation and Induced Apoptosis of Activated HSC-T6 Cells. |
| Q34568791 | Lineage tracing reveals distinctive fates for mesothelial cells and submesothelial fibroblasts during peritoneal injury |
| Q38563744 | Linking immune responses with fibrosis in allergic eye disease |
| Q42206856 | Liraglutide improves liver microvascular dysfunction in cirrhosis: Evidence from translational studies. |
| Q38190875 | Liver fibrosis and repair: immune regulation of wound healing in a solid organ |
| Q39065620 | Liver inflammation and fibrosis |
| Q90447957 | Liver repair and regeneration after ischemia-reperfusion injury is associated with prolonged fibrosis |
| Q38240680 | Liver sinusoidal endothelial cells in hepatic fibrosis |
| Q36720404 | Long noncoding RNAs expressed in human hepatic stellate cells form networks with extracellular matrix proteins |
| Q33587672 | Loss of pericyte smoothened activity in mice with genetic deficiency of leptin |
| Q38918649 | Macrophage Phenotype in Liver Injury and Repair |
| Q36826814 | Matricellular protein CCN1 promotes regression of liver fibrosis through induction of cellular senescence in hepatic myofibroblasts. |
| Q42480775 | Matrix and cell phenotype differences in Dupuytren's disease |
| Q26852563 | Matrix biology of idiopathic pulmonary fibrosis: a workshop report of the national heart, lung, and blood institute |
| Q38653648 | Mechanical control of cardiac myofibroblasts |
| Q39130195 | Mechanism of impairment on liver regeneration in elderly patients: Role of hepatic stellate cell function |
| Q90424470 | Mechanisms for the Resolution of Organ Fibrosis |
| Q36885732 | Mechanisms of Lung Fibrosis Resolution |
| Q39294420 | Mechanisms of hepatic stellate cell activation |
| Q26800298 | Mechanisms of liver fibrosis resolution |
| Q43159830 | Mechanoregulation of the Myofibroblast in Wound Contraction, Scarring, and Fibrosis: Opportunities for New Therapeutic Intervention |
| Q47205718 | Mechanosensing and fibrosis |
| Q50445895 | Melatonin inhibits autophagy and endoplasmic reticulum stress in mice with carbon tetrachloride-induced fibrosis |
| Q50456374 | Melatonin limits the expression of profibrogenic genes and ameliorates the progression of hepatic fibrosis in mice. |
| Q36560851 | Mesenchymal stem cells and their secreted molecules predominantly ameliorate fulminant hepatic failure and chronic liver fibrosis in mice respectively |
| Q42716957 | Mesodermal mesenchymal cells give rise to myofibroblasts, but not epithelial cells, in mouse liver injury |
| Q37730676 | Mesothelin/mucin 16 signaling in activated portal fibroblasts regulates cholestatic liver fibrosis. |
| Q92156218 | Metabolic Hallmarks of Hepatic Stellate Cells in Liver Fibrosis |
| Q44765599 | MicroRNA-101 suppresses liver fibrosis by targeting the TGFβ signalling pathway |
| Q54328253 | MicroRNA-155 attenuates activation of hepatic stellate cell by simultaneously preventing EMT process and ERK1 signalling pathway. |
| Q36719130 | MicroRNA-378 limits activation of hepatic stellate cells and liver fibrosis by suppressing Gli3 expression |
| Q64257685 | MicroRNA29a Reverts the Activated Hepatic Stellate Cells in the Regression of Hepatic Fibrosis through Regulation of ATPase H⁺ Transporting V1 Subunit C1 |
| Q37509308 | Microvascular pericytes in healthy and diseased kidneys |
| Q99609304 | Mitochondrial dysfunction in fibrotic diseases |
| Q39151653 | Modulation of hepatic stellate cells and reversibility of hepatic fibrosis |
| Q28077583 | Molecular Cues Guiding Matrix Stiffness in Liver Fibrosis |
| Q51713351 | Molecular and Cellular Functions Distinguish Superior Therapeutic Efficiency of Bone Marrow CD45 Cells Over Mesenchymal Stem Cells in Liver Cirrhosis. |
| Q101133373 | Molecular and cellular mechanisms of liver fibrosis and its regression |
| Q90348644 | Molecular determinants of mesenchymal cell activation in fibroproliferative diseases |
| Q38684604 | Molecular interplays in hepatic stellate cells: apoptosis, senescence, and phenotype reversion as cellular connections that modulate liver fibrosis |
| Q27692609 | Molecular mechanism and treatment of viral hepatitis-related liver fibrosis |
| Q38831961 | Molecular networks underlying myofibroblast fate and fibrosis |
| Q47097563 | Morin enhances hepatic Nrf2 expression in a liver fibrosis rat model |
| Q38553312 | Morphogen-related therapeutic targets for liver fibrosis |
| Q37210744 | Mouse model of chronic and binge ethanol feeding (the NIAAA model) |
| Q38925162 | Myofibroblasts and inflammatory cells as players of cardiac fibrosis |
| Q37262528 | Myofibroblasts in Fibrotic Kidneys |
| Q27692541 | Myofibroblasts: trust your heart and let fate decide. |
| Q36288405 | New Approaches for Studying Alcoholic Liver Disease |
| Q38873303 | New Developments on the Treatment of Liver Fibrosis |
| Q38553309 | New therapies for hepatic fibrosis |
| Q64290118 | Nitro-fatty acids protect against steatosis and fibrosis during development of nonalcoholic fatty liver disease in mice |
| Q50228094 | No significant impact of Foxf1 siRNA treatment in acute and chronic CCl4 liver injury |
| Q38705659 | Non-alcoholic steatohepatitis: emerging molecular targets and therapeutic strategies |
| Q96640997 | Non-invasive monitoring of chronic liver disease via near-infrared and shortwave-infrared imaging of endogenous lipofuscin |
| Q94521157 | Novel Combinatorial Regimen of Garcinol and Curcuminoids for Non-alcoholic Steatohepatitis (NASH) in Mice |
| Q26852520 | Novel insights into pericyte-myofibroblast transition and therapeutic targets in renal fibrosis |
| Q35622533 | Novel insights into the function and dynamics of extracellular matrix in liver fibrosis |
| Q91876572 | Origin and role of hepatic myofibroblasts in hepatocellular carcinoma |
| Q36264658 | Origin of fibrosing cells in systemic sclerosis |
| Q38243843 | Origin of myofibroblasts and cellular events triggering fibrosis |
| Q34060761 | Origin of myofibroblasts in the fibrotic liver in mice |
| Q38139402 | Origins of fibrosis: pericytes take centre stage |
| Q34791455 | Osteopontin deficiency does not prevent but promotes alcoholic neutrophilic hepatitis in mice. |
| Q35908145 | Osthole ameliorates hepatic fibrosis and inhibits hepatic stellate cell activation |
| Q58122659 | P311, Friend, or Foe of Tissue Fibrosis? |
| Q41505272 | PAK proteins and YAP-1 signalling downstream of integrin beta-1 in myofibroblasts promote liver fibrosis |
| Q34462733 | Pathobiology of liver fibrosis: a translational success story |
| Q64116952 | Pathological mechanisms and therapeutic outlooks for arthrofibrosis |
| Q34357219 | Pericytes at the intersection between tissue regeneration and pathology |
| Q93155221 | Phenotypical and Functional Polymorphism of Liver Resident Macrophages |
| Q34044638 | Platelet-derived growth factor primes cancer-associated fibroblasts for apoptosis. |
| Q38322997 | Portal Fibroblasts in Biliary Fibrosis |
| Q35494410 | Potent natural products and herbal medicines for treating liver fibrosis |
| Q26750543 | Potential effects of curcumin on peroxisome proliferator-activated receptor-γ in vitro and in vivo |
| Q38237617 | Preparing the ground for tissue regeneration: from mechanism to therapy |
| Q94564532 | Pro- and Anti-fibrogenic Functions of Gram-Negative Bacterial Lipopolysaccharide in the Liver |
| Q37149911 | Progressive Fibrosis Is Driven by Genetic Predisposition, Allo-immunity, and Inflammation in Pediatric Liver Transplant Recipients. |
| Q38719582 | Protective effect of human serum amyloid P on CCl4-induced acute liver injury in mice |
| Q37713034 | Quantitative Proteomic analysis on Activated Hepatic Stellate Cells reversion Reveal STAT1 as a key regulator between Liver Fibrosis and recovery |
| Q41860012 | Quiescent hepatic stellate cells functionally contribute to the hepatic innate immune response via TLR3. |
| Q38419194 | Recent advancement of molecular mechanisms of liver fibrosis |
| Q43105339 | Recent advances in pediatric gastroenterology, hepatology and nutrition |
| Q92879280 | Regeneration of Dermis: Scarring and Cells Involved |
| Q35867605 | Regulatory Effects and Mechanism of Adenovirus-Mediated PTEN Gene on Hepatic Stellate Cells |
| Q28083461 | Relationship of and cross-talk between physical and biologic properties of the glomerulus |
| Q47966144 | Relaxin modulates human and rat hepatic myofibroblast function and ameliorates portal hypertension in vivo |
| Q38531955 | Renal erythropoietin-producing cells in health and disease. |
| Q41986595 | Reproducibility of shear wave elastography (SWE) in patients with chronic liver disease. |
| Q38065650 | Resident mesenchymal cells and fibrosis |
| Q52687459 | Resolution of organ fibrosis. |
| Q58742663 | Retinoids Issued from Hepatic Stellate Cell Lipid Droplet Loss as Potential Signaling Molecules Orchestrating a Multicellular Liver Injury Response |
| Q92350016 | Retinoids in Stellate Cells: Development, Repair, and Regeneration |
| Q38974002 | Reversal of liver cirrhosis: current evidence and expectations |
| Q33731308 | Reversal, maintenance or progression: what happens to the liver after a virologic cure of hepatitis C? |
| Q27026622 | Reversibility and heritability of liver fibrosis: Implications for research and therapy |
| Q37132266 | Reversibility of Liver Fibrosis and Inactivation of Fibrogenic Myofibroblasts |
| Q36373253 | Reversibility of Stricturing Crohn's Disease-Fact or Fiction? |
| Q26822053 | Reversibility of liver fibrosis |
| Q38886975 | Reversibility of liver fibrosis. |
| Q61807550 | Reversion of in vivo fibrogenesis by novel chromone scaffolds |
| Q38175465 | Review article: The prevention and reversal of hepatic fibrosis in autoimmune hepatitis |
| Q38218544 | Review article: the efficacy of biomarkers in chronic fibroproliferative diseases - early diagnosis and prognosis, with liver fibrosis as an exemplar. |
| Q38042443 | Review article: the reversibility of cirrhosis |
| Q38479922 | Role of TGF-β signaling in differentiation of mesothelial cells to vitamin A-poor hepatic stellate cells in liver fibrosis |
| Q34123206 | Role of adenosine A2B receptor signaling in contribution of cardiac mesenchymal stem-like cells to myocardial scar formation. |
| Q36746393 | Role of differentiation of liver sinusoidal endothelial cells in progression and regression of hepatic fibrosis in rats |
| Q64077761 | Role of the Gut-Liver Axis in Liver Inflammation, Fibrosis, and Cancer: A Special Focus on the Gut Microbiota Relationship |
| Q90437359 | Roles of the endoplasmic reticulum-resident, collagen-specific molecular chaperone Hsp47 in vertebrate cells and human disease |
| Q38427366 | SILAC-based quantitative proteomic analysis of secretome between activated and reverted hepatic stellate cells |
| Q47129673 | SOX9 predicts progression toward cirrhosis in patients while its loss protects against liver fibrosis. |
| Q60302322 | Selective overexpression of cytoglobin in stellate cells attenuates thioacetamide-induced liver fibrosis in mice |
| Q38961328 | Senescence in hepatic stellate cells as a mechanism of liver fibrosis reversal: a putative synergy between retinoic acid and PPAR-gamma signalings |
| Q35944077 | Serum Amyloid A Induces Inflammation, Proliferation and Cell Death in Activated Hepatic Stellate Cells |
| Q43083609 | Small molecule-mediated inhibition of myofibroblast transdifferentiation for the treatment of fibrosis |
| Q36890924 | Smoothened is a master regulator of adult liver repair |
| Q33907049 | Sphingosine-1-Phosphate Prevents Egress of Hematopoietic Stem Cells From Liver to Reduce Fibrosis. |
| Q33687809 | Src-homology protein tyrosine phosphatase-1 agonist, SC-43, reduces liver fibrosis. |
| Q38718555 | Stearoyl-CoA Desaturase Promotes Liver Fibrosis and Tumor Development in Mice via a Wnt Positive-Signaling Loop by Stabilization of Low-Density Lipoprotein-Receptor-Related Proteins 5 and 6. |
| Q28082065 | Strategies and endpoints of antifibrotic drug trials: Summary and recommendations from the AASLD Emerging Trends Conference, Chicago, June 2014. |
| Q42983922 | Strategies to Detect Hepatic Myofibroblasts in Liver Cirrhosis of Different Etiologies |
| Q30854135 | Substrate Rigidity Controls Activation and Durotaxis in Pancreatic Stellate Cells |
| Q47230773 | Synectin promotes fibrogenesis by regulating PDGFR isoforms through distinct mechanisms |
| Q92012591 | Synergy of Phospholipid-Drug Formulations Significantly Deactivates Profibrogenic Human Hepatic Stellate Cells |
| Q92731034 | Systemic Sclerosis Serum Steers the Differentiation of Adipose-Derived Stem Cells Toward Profibrotic Myofibroblasts: Pathophysiologic Implications |
| Q35864472 | TGF-β-Dependent Dendritic Cell Chemokinesis in Murine Models of Airway Disease. |
| Q45652001 | TWEAK-Fn14 Signaling Activates Myofibroblasts to Drive Progression of Fibrotic Kidney Disease. |
| Q89461013 | Taming the Savage Beast from Within - Tcf21, a Novel Regulator of Stellate Cell Deactivation |
| Q47252515 | Targeted apoptosis of myofibroblasts with the BH3 mimetic ABT-263 reverses established fibrosis |
| Q57111070 | Targeting Endothelial Erk1/2-Akt Axis as a Regeneration Strategy to Bypass Fibrosis during Chronic Liver Injury in Mice |
| Q95270458 | Targeting Hepatic Stellate Cells for the Treatment of Liver Fibrosis by Natural Products: Is It the Dawning of a New Era? |
| Q42725773 | Targeting Liver Fibrosis with a Cell-penetrating Protease-activated Receptor-2 (PAR2) Pepducin |
| Q43207025 | Targeting cardiac fibroblasts: the pressure is on. |
| Q48042066 | Tensile forces drive a reversible fibroblast-to-myofibroblast transition during tissue growth in engineered clefts. |
| Q64066713 | The Effect of Splenectomy on the Reversal of Cirrhosis: a Prospective Study |
| Q38774776 | The Promise of New Technologies to Reduce, Refine, or Replace Animal Use while Reducing Risks of Drug Induced Liver Injury in Pharmaceutical Development |
| Q61450263 | The Role of S1P and the Related Signaling Pathway in the Development of Tissue Fibrosis |
| Q33737254 | The Soft- and Hard-Heartedness of Cardiac Fibroblasts: Mechanotransduction Signaling Pathways in Fibrosis of the Heart |
| Q64230573 | The Wilms' tumor suppressor gene regulates pancreas homeostasis and repair |
| Q89769221 | The balancing act of the liver: tissue regeneration versus fibrosis |
| Q38945443 | The characteristics of activated portal fibroblasts/myofibroblasts in liver fibrosis |
| Q84743162 | The elusive source of myofibroblasts: problem solved? |
| Q40408671 | The fibrolytic potentials of vitamin D and thymoquinone remedial therapies: insights from liver fibrosis established by CCl4 in rats |
| Q38806808 | The histological quantification of alpha-smooth muscle actin predicts future graft fibrosis in pediatric liver transplant recipients. |
| Q93013140 | The life cycle of cancer-associated fibroblasts within the tumour stroma and its importance in disease outcome |
| Q89989458 | The mechanism and role of intracellular α-ketoglutarate reduction in hepatic stellate cell activation |
| Q38896147 | The mechanisms of HSC activation and epigenetic regulation of HSCs phenotypes |
| Q26751250 | The myofibroblast in wound healing and fibrosis: answered and unanswered questions |
| Q38673061 | The myofibroblast, a key cell in normal and pathological tissue repair. |
| Q89769218 | The perivascular origin of pathological fibroblasts |
| Q36931974 | The role of IL-17 signaling in regulation of the liver-brain axis and intestinal permeability in Alcoholic Liver Disease |
| Q38952244 | The role of cardiac fibroblasts in post-myocardial heart tissue repair |
| Q38246646 | The role of pericyte detachment in vascular rarefaction |
| Q41592684 | The type I insulin-like growth factor regulates the liver stromal response to metastatic colon carcinoma cells |
| Q38237634 | The types of hepatic myofibroblasts contributing to liver fibrosis of different etiologies |
| Q41476840 | Three-dimensional biomimetic vascular model reveals a RhoA, Rac1, and N-cadherin balance in mural cell-endothelial cell-regulated barrier function |
| Q36101672 | Tissue-type plasminogen activator suppresses activated stellate cells through low-density lipoprotein receptor-related protein 1 |
| Q39433671 | Tracking Adventitial Fibroblast Contribution to Disease: A Review of Current Methods to Identify Resident Fibroblasts |
| Q64263531 | Transcriptional regulation of Hepatic Stellate Cell activation in NASH |
| Q58754397 | Transforming Growth Factor-β-Induced Cell Plasticity in Liver Fibrosis and Hepatocarcinogenesis |
| Q36511515 | Transforming growth factor β-1 stimulates profibrotic epithelial signaling to activate pericyte-myofibroblast transition in obstructive kidney fibrosis. |
| Q42315013 | Tricyclic Antidepressants Promote Ceramide Accumulation to Regulate Collagen Production in Human Hepatic Stellate Cells. |
| Q93336606 | Turning foes to friends: targeting cancer-associated fibroblasts |
| Q41807071 | Varying RGD concentration and cell phenotype alters the expression of extracellular matrix genes in vocal fold fibroblasts |
| Q87161188 | Vitamin A and insulin are required for the maintenance of hepatic stellate cell quiescence |
| Q34253198 | Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy |
| Q85855129 | [Liver fibrogenesis: physiopathology] |
| Q29144909 | p62/SQSTM1 by Binding to Vitamin D Receptor Inhibits Hepatic Stellate Cell Activity, Fibrosis, and Liver Cancer |
Search more.